Curetis lower respiratory tract panel read...Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections. more ➔
Merck and Broad Institute announce CRISPR... Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing. more ➔
Billions for the circular economyTogether with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy. more ➔
Genmab launches US$502m IPODanish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline. more ➔
AM-Pharma raises €116m for Phase IIIDutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III. more ➔
US$5bn deal for GalapagosBelgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform. more ➔
Boehringer snaps up cancer vaccine develop... German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics. more ➔
€28.5m for microalgae expert MicrophytFrench microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics. more ➔
€8m for universal flu vaccine French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium. more ➔
BioNTech pulls in massive €290m financin...It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost … more ➔
